Strong Revenue Growth
Total revenues of $1.37 billion and product sales of $1.15 billion, representing a 20% and 19% increase, respectively, versus prior year.
Jakafi Performance
Jakafi Q3 sales reached $791 million, a 7% increase with strong demand growth of 10% year-over-year.
Opzelura Sales Surge
Opzelura sales reached $188 million, a 35% increase versus prior year. Sales in the U.S. were $144 million, a 21% increase.
Niktimvo Launch Success
Niktimvo sales in the third quarter totaled $46 million, an increase of 27% versus the second quarter.
Pipeline and R&D Focus
Strategic focus on high-value programs and key updates in solid tumor and povorcitinib programs.